SOPHiA GENETICS has entered a global partnership with AstraZeneca to develop, validate and launch two companion diagnostics aimed at supporting precision oncology therapies.
This newly established multi-year agreement involves both companies working together to advance companion diagnostic programmes that will leverage Sophia Genetics’ decentralised clinical trial assays alongside AstraZeneca’s therapies.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under the contract, Sophia Genetics is tasked with developing its Solid Tumor application as a decentralised companion diagnostic.
The company will also create and validate a haematological oncology application to support a companion diagnostic initiative for blood cancer patients.
The intention is for these solutions to be available across laboratories and geographic locations at the point of therapy launch.
Sophia Genetics CEO Ross Muken said: “A breakthrough therapy only matters to the patients we can find in time to treat. We are moving towards a future that no longer depends on geography, where any laboratory can run the same test to the same high standard on day one of a launch.
“We believe these programmes are what that future looks like in practice. Bringing the right therapy to the right patient, in any country and any laboratory, is the work that will define the next generation of precision medicine.”
Sophia Genetics aims to combine biomarker detection with rapid deployment to reduce the time between new therapy availability and patient access.
The company’s data-driven platform facilitates analysis of patient populations, aiming to assist clinical decision-making within healthcare systems worldwide.
Its companion diagnostic capabilities include clinical trial assay development to support patient enrolment, as well as the processes needed for validation and regulatory submissions in the EU, Japan, the US and other regions.
Deployment via the SOPHiA DDM Platform and MaxCare Program allows laboratories to locally adopt new genomic applications.
In November 2025, Sophia Genetics and Element Biosciences collaborated to advance genomic sequencing and workflows for precision medicine.
